About This Console

What Doctor Sermorelin Is

Doctor Sermorelin indexes the peer-reviewed literature on Sermorelin (GHRH(1-29)-NH2) — reading each study, logging it, and citing it. No clinic stands behind the index: it employs no clinicians, offers no medical advice, and has no product to make, stock, or sell. It reads published science and pins it to source, and that is the whole function.

The 'Doctor' modifier is a framing device — it locates this publication relative to the clinical research literature, not relative to any medical service. No physicians, pharmacists, or clinical staff work here, and no treatment, consultation, or prescription of any kind is on offer.

Every entry draws on peer-reviewed journals, FDA regulatory documents, and WADA anti-doping methodology papers, and every number carries an inline citation to a specific publication.

Sermorelin FDA Approval History

Sermorelin (Geref, NDA 20-443) received FDA approval on September 26, 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure. A diagnostic-use formulation (NDA 19-863) was approved December 28, 1990 ^[15].

The manufacturer (EMD Serono) voluntarily withdrew both products from the market in 2008–2009. The FDA published a determination in the Federal Register in March 2013 confirming that the withdrawal was not for reasons of safety or effectiveness ^[15].

Sermorelin is currently available in the United States via 503A and 503B compounding pharmacies as a compounded prescription medication. It is not a controlled substance under the DEA Controlled Substances Act.

For sermorelin FDA approval history context, the regulatory status is clearly: formerly approved, commercially withdrawn for non-safety reasons, currently compounded.

Sermorelin Legal Status for Research

Sermorelin is a formerly FDA-approved compound now available as a compounded prescription medication under Section 503A/503B of the FD&C Act ^[15]. It is not classified as a research chemical in the same regulatory space as unapproved peptides; it has an NDA history.

WADA classifies sermorelin as prohibited under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics — for competitive athletes in sports that adopt the WADA Prohibited List ^[16]. This prohibition applies to any dose and any route of administration.

In the United States, possession and use of compounded sermorelin with a valid prescription is legal. The compound's regulatory status differs by jurisdiction — non-U.S. regulatory frameworks are not covered on this site.

Sermorelin and Anti-Doping Status

WADA prohibits sermorelin under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) ^[16]. The prohibition is categorical. WADA-certified laboratories have validated LC-MS/MS and nano-LC-Q/Orbitrap MS detection methods at ≤0.5 ng/mL in urine ^[20]. Sermorelin analogs are identified via 19 in vitro metabolite reference standards in the anti-doping laboratory toolkit ^[16].

Why is Sermorelin banned in sports? It stimulates endogenous GH production, which is itself prohibited at supraphysiologic concentrations under the WADA Prohibited List. GHRH-mediated GH elevation is treated as functionally equivalent to prohibited GH administration for anti-doping purposes.